ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL141
CHEMBL141
Compound Name LAMIVUDINE
ChEMBL Synonyms GR 109714X | EPIVIR | EPIVIR-HBV | LAMIVUDINE | ZEFFIX
Max Phase 4 (Approved)
Trade Names EPIVIR | LAMIVUDINE | ZEFFIX | EPIVIR-HBV
Molecular Formula C8H11N3O3S

Additional synonyms for CHEMBL141 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES NC1=NC(=O)N(C=C1)[C@@H]2CS[C@H](CO)O2
Standard InChI InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6 ...
Download InChI
Standard InChI Key JTEGQNOMFQHVDC-NKWVEPMBSA-N

Sources

  • AstraZeneca Deposited Data
  • British National Formulary
  • DrugMatrix
  • Orange Book
  • PubChem BioAssays
  • Scientific Literature
  • TP-search Transporter Database
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL141

Molecule Features

CHEMBL141 compound icon
Drug Type:Natural Product-derived Rule of Five:Y First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
DNA inhibitor DNA DailyMed
DNA inhibitor DNA DailyMed
DNA inhibitor DNA DailyMed
DNA polymerase/reverse transcriptase inhibitor DNA polymerase/reverse transcriptase DailyMed
Human immunodeficiency virus type 1 reverse transcriptase inhibitor Human immunodeficiency virus type 1 reverse transcriptase DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
HIV InfectionsD015658EFO:0000180HIV-1 infection4ClinicalTrials
DailyMed
FDA
DiarrheaD003967HP:0002014diarrhea3ClinicalTrials
HIV InfectionsD015658EFO:0000764HIV infection4ClinicalTrials
DailyMed
DailyMed
DailyMed
FDA
Liver CirrhosisD008103EFO:0001422cirrhosis of liver1ClinicalTrials
Sarcoma, KaposiD012514EFO:0000558Kaposi's sarcoma2ClinicalTrials
Hepatitis B, ChronicD019694EFO:0004239chronic hepatitis B infection4ClinicalTrials
DailyMed
Paraparesis, Tropical SpasticD015493EFO:0007527tropical spastic paraparesis2ClinicalTrials
InflammationD007249MP:0001845inflammation4DailyMed
LymphomaD008223EFO:0000574lymphoma2ClinicalTrials
Carcinoma, HepatocellularD006528EFO:0000182hepatocellular carcinoma3ClinicalTrials
Hepatitis B, ChronicD019694EFO:0004197hepatitis B infection4ClinicalTrials
Lymphoma, Non-HodgkinD008228EFO:0005952non-Hodgkins lymphoma2ClinicalTrials
Hepatitis BD0065094DailyMed
InfectionD007239EFO:0000544infection4ClinicalTrials
FDA
Acquired Immunodeficiency SyndromeD000163EFO:0000765AIDS3ClinicalTrials

Clinical Data

ClinicalTrials.gov LAMIVUDINE
The Cochrane Collaboration LAMIVUDINE

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL141. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL1293237 Bloom syndrome protein Homo sapiens 0.883
CHEMBL247 Human immunodeficiency virus type 1 reverse transcriptase Human immunodeficiency virus 1 0.555
CHEMBL3251 Nuclear factor NF-kappa-B p105 subunit Homo sapiens 0.288

10uM


ChEMBL_ID Target Name Organism Score
CHEMBL2366516 Reverse transcriptase Human immunodeficiency virus 1 0.904
CHEMBL1293237 Bloom syndrome protein Homo sapiens 0.390
CHEMBL5328 Thymidylate synthase Lactobacillus casei 0.262

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
229.3 229.0521 -0.59 2 90.37 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
7 2 0 6 3 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
13.83 4.18 -.51 -.51 1 15 0.7

Structural Alerts

There are no structural alerts for CHEMBL141

Compound Cross References

ATC J - ANTIINFECTIVES FOR SYSTEMIC USE
J05 - ANTIVIRALS FOR SYSTEMIC USE
J05A - DIRECT ACTING ANTIVIRALS
J05AF - Nucleoside and nucleotide reverse transcriptase inhibitors
J05AF05 - lamivudine

ChemSpider ChemSpider:JTEGQNOMFQHVDC-NKWVEPMBSA-N
DailyMed lamivudine
PubChem SID: 29215254 SID: 49681736
Wikipedia Lamivudine

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL141



BindingDB 50366817
Brenda 6246
ChEBI 63577
ChemicalBook CB1290608
DrugBank DB00709
DrugCentral 1539
eMolecules 2726078 1987423 31588897
FDA SRS 2T8Q726O95
Human Metabolome Database HMDB0014847
IBM Patent System F739F4A9EC506BBAA7FFAF9B138C1CD3
KEGG Ligand C07065
LINCS LSM-5215
Mcule MCULE-8483986532 MCULE-2096184994
MolPort MolPort-002-507-347
NIH Clinical Collection SAM002589994 SAM001246582
Nikkaji J457.051K
PDBe 3TC
PharmGKB PA450163
PubChem 60825
PubChem: Drugs of the Future 12014700
PubChem: Thomson Pharma 15121620 14798125
Selleck Lamivudine(Epivir)
SureChEMBL SCHEMBL109675
ZINC ZINC000000012346

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/JTEGQNOMFQHVDC-NKWVEPMBSA-N spacer
spacer